EU Medicines Marketed by Our Partners

All product information provided is intended for the European Union audience only.

These products may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.

EU Medicines Made Available by Our Partners

All therapeutic information provided is intended for the European Union audience only.

These treatments may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.

We have granted licenses to medicines or to technologies which enable third parties to develop, provide and, in some cases, manufacture.

Such arrangements in the EU include the following:

About Nektar Therapeutics and AstraZeneca Agreement for MOVENTIG in the EU

Under our global agreement with AstraZeneca for MOVENTIG (MOVANTIK in the U.S.), AstraZeneca is responsible for all development and commercialization.

Nektar Therapeutics and Baxalta (a division of Shire plc) Agreement for ADYNOVATE/ADYNOVI

Under a collaboration with Baxter and then Baxalta, we developed ADYNOVATE, an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia. In January 2019, Takeda Pharmaceutical Company Limited acquired Baxalta and ADYNOVATE through its acquisition of Shire plc.

EU Medicines Using Our Technologies

We have granted licenses to our technologies which enable third parties to develop, commercialize and, in some cases, manufacture.

MOVENTIG is a trademark of the AstraZeneca group of companies. AstraZeneca‘s partner, Kyowa Kirrin, markets MOVENTIG in the EU.